权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Proteomic analysis of cancer associated proteins in the solid neoplasm -The analysis for individualized therapy for lung cancer-

实体瘤中癌症相关蛋白的蛋白质组学分析-肺癌个体化治疗分析-

基本信息

批准号：
15390423
负责人：
HIRANO Takashi
金额：
$ 5.31万
依托单位：
Tokyo Medical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2005
项目状态：
已结题

项目摘要

1.Gel based proteomics(1)Analysis of proteins associated with histopathological types of lung cancer : 47 proteins (15 adenocarcinoma associated proteins, 16 squamous cell carcinoma associated proteins and 16 neuroendocrine carcinoma associated proteins) were identified using 2 dimensional polyacrylamide gel electrophoresis (2DE) and mass spectrometry (MS). The validation analysis is on going. We suggest the possibility of the classification based on proteomic profiles and the selection of the therapeutic strategy.(2)Analysis of CDDP resistance associated proteins : The spots of GST-π and reticulocalbin (RCN) were identified on 2DE gel, and we proposed the possibility that the responders for platinum based chemotherapy were selected postoperatively. Furthermore, we detected 107 proteins with more than 1.5 fold overexpression and 120 proteins with less than 0.75 fold reduced expression using Ettan DIGE System.(3)We detected 40 and 33 proteins in which the expression levels were changed … More by two kinds of tyrosine kinase inhibitors. These protein molecules were identified by MS, and sequentially we are carrying out the validation analysis.2.Proteomic analysis using Liquid Chromatography-MS (LC-MS)(1)Analysis of lymph node involvement associated proteins in lung adenocarcinoma : We compared protein expression profiles between t2 no cases and t1 n(+) cases. We detected 604 candidate proteins associated with lymph node involvement. The identification and validation are on going.(2)Exploration of the biomarkers for the early detection of lung adenocarcinoma : We analyzed sera of the patients with stage IA and stage III adenocarcinomas, and thirty candidate biomarkers for early detection were detected. We validated seven candidate proteins using already established assay systems. The values of some candidate proteins were elevated in the sera of adenocarcinoma patients, but there are no statistically significant differences between the sera of adenocarcinoma patients and healthy donors. Therefore, we did not recognize the usefulness of the biomarlcers for early detection.There is a high possibility that the classification based on proteomic profile reflects biological characteristics of cancerous cells. We schedule the further investigations and evaluations for the follow-up and therapeutic strategies towards the individualized therapy of lung cancer patients. Less

1.（1）与肺癌组织病理学类型相关的蛋白质组学分析：采用双向凝胶电泳（2DE）和质谱（MS）技术，共鉴定出47个蛋白质，其中腺癌相关蛋白15个，鳞癌相关蛋白16个，神经内分泌癌相关蛋白16个。验证分析正在进行中。我们建议的可能性的分类的基础上的蛋白质组学概况和选择的治疗策略。（2）CDDP耐药相关蛋白分析：在2DE凝胶上鉴定GST-π和网织红蛋白（RCN）的斑点，提出了筛选术后铂类化疗有效者的可能性。此外，我们使用Ettan DIGE系统检测到107种蛋白质的过表达超过1.5倍，120种蛋白质的表达降低小于0.75倍。(3)We检测到40个和33个蛋白质的表达水平发生了变化 ...更多信息两种酪氨酸激酶抑制剂的作用。2.液相色谱-质谱（LC-MS）法蛋白质组学分析（1）肺腺癌淋巴结转移相关蛋白质分析：比较t2 no和t1 n（+）病例的蛋白质表达谱。我们检测到604个与淋巴结受累相关的候选蛋白。鉴定和验证正在进行中。（2）肺腺癌早期诊断的生物标志物的筛选：通过对IA期和III期肺腺癌患者血清的分析，筛选出30个早期诊断的候选生物标志物。我们使用已经建立的测定系统验证了七种候选蛋白质。腺癌患者血清中某些候选蛋白的值升高，但腺癌患者血清与健康献血员血清之间无统计学差异。因此，我们没有认识到这些标记物对早期检测的有用性。基于蛋白质组学谱的分类很有可能反映癌细胞的生物学特征。我们计划对肺癌患者的随访和治疗策略进行进一步的调查和评估，以实现肺癌患者的个体化治疗。少